| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.0035 | 0.9 |
| mRNA | NSC 74859 | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | GSK-650394 | GDSC1000 | pan-cancer | AAC | 0.0022 | 0.9 |
| mRNA | dacarbazine | CTRPv2 | pan-cancer | AAC | -0.002 | 1 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | -0.0032 | 1 |
| mRNA | Talazoparib | GDSC1000 | pan-cancer | AAC | 0.0019 | 1 |
| mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | -0.003 | 1 |
| mRNA | BRD-K86535717 | CTRPv2 | pan-cancer | AAC | -0.0036 | 1 |
| mRNA | Sorafenib | CCLE | pan-cancer | AAC | -0.0021 | 1 |